These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 2552552)

  • 1. [Treatment of deep venous thrombosis. Comparative study of a low molecular weight heparin fragment (Fragmin) by the subcutaneous route and standard heparin by the continuous intravenous route. A multicenter study].
    Aiach M; Fiessinger JN; Vitoux JF; Derlon A; Grollier G; Le Querrec A; Gouault-Heilmann M; Huet Y; Franco A; Polack B; Pouzol P; Dubois A; Schved JF; Boneu B; Guittard J; Sie P; Heilmann JJ; Kher A; Haye I
    Rev Med Interne; 1989; 10(4):375-81. PubMed ID: 2552552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT).
    Bratt G; Aberg W; Johansson M; Törnebohm E; Granqvist S; Lockner D
    Thromb Haemost; 1990 Dec; 64(4):506-10. PubMed ID: 1964751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experiences in the administration of a low molecular weight heparin (Fragmin, Kabi-Vitrum) to healthy volunteers and in the treatment of established deep venous thrombosis.
    Bratt GA; Törnebohm E; Johanson M; Aberg W; Granqvist S; Lockner D
    Acta Chir Scand Suppl; 1988; 543():96-100. PubMed ID: 2847465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous and subcutaneous administration of Fragmin in deep venous thrombosis.
    Lockner D; Bratt G; Törnebohm E; Aberg W; Granqvist S
    Haemostasis; 1986; 16 Suppl 2():25-9. PubMed ID: 3744133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis.
    Lindmarker P; Holmström M; Granqvist S; Johnsson H; Lockner D
    Thromb Haemost; 1994 Aug; 72(2):186-90. PubMed ID: 7831649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fragmin once or twice daily subcutaneously in the treatment of deep venous thrombosis of the leg.
    Holmoström M; Berglund MC; Granquist S; Bratt G; Törnebohm E; Lockner D
    Thromb Res; 1992 Jul; 67(1):49-55. PubMed ID: 1332213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
    Harenberg J; Stehle G; Blauth M; Huck K; Mall K; Heene DL
    Semin Thromb Hemost; 1997; 23(1):83-90. PubMed ID: 9156415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of deep venous thrombosis with low molecular weight heparin (Fragmin)].
    Nesvold A; Ly B; Abildgaard U; Stiris M
    Tidsskr Nor Laegeforen; 1991 Nov; 111(27):3296-7. PubMed ID: 1659751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis.
    Simonneau G; Charbonnier B; Decousus H; Planchon B; Ninet J; Sie P; Silsiguen M; Combe S
    Arch Intern Med; 1993 Jul; 153(13):1541-6. PubMed ID: 8391792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of the effectiveness and safety of Fragmin (Kabi 2165) versus calcium heparin in the prevention of deep venous thrombosis in general surgery].
    Creperio G; Marabini M; Ciocia G; Bergonzi M; Fincato M
    Minerva Chir; 1990 Sep; 45(17):1101-6. PubMed ID: 2177861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis.
    Fiessinger JN; Lopez-Fernandez M; Gatterer E; Granqvist S; Kher A; Olsson CG; Söderberg K
    Thromb Haemost; 1996 Aug; 76(2):195-9. PubMed ID: 8865530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicentre study.
    Thromb Haemost; 1991 Mar; 65(3):251-6. PubMed ID: 1646490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group.
    Kirchmaier CM; Wolf H; Schäfer H; Ehlers B; Breddin HK
    Int Angiol; 1998 Sep; 17(3):135-45. PubMed ID: 9821025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study.
    Albada J; Nieuwenhuis HK; Sixma JJ
    Circulation; 1989 Oct; 80(4):935-40. PubMed ID: 2551537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind randomized placebo controlled trial of thromboprophylaxis in major elective general surgery using once daily injections of a low molecular weight heparin fragment (Fragmin).
    Ockelford PA; Patterson J; Johns AS
    Thromb Haemost; 1989 Dec; 62(4):1046-9. PubMed ID: 2559484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis.
    Riess H; Koppenhagen K; Tolle A; Kemkes-Matthes B; Gräve M; Patek F; Drexler M; Siemens HJ; Harenberg J; Weidinger G; Brom J; Haas S;
    Thromb Haemost; 2003 Aug; 90(2):252-9. PubMed ID: 12888872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Fragmin-Study Group.
    Alhenc-Gelas M; Jestin-Le Guernic C; Vitoux JF; Kher A; Aiach M; Fiessinger JN
    Thromb Haemost; 1994 Jun; 71(6):698-702. PubMed ID: 7974334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosis.
    Harenberg J; Huck K; Bratsch H; Stehle G; Dempfle CE; Mall K; Blauth M; Usadel KH; Heene DL
    Haemostasis; 1990; 20 Suppl 1():205-19. PubMed ID: 1964663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators.
    Harenberg J; Schmidt JA; Koppenhagen K; Tolle A; Huisman MV; Büller HR
    Thromb Haemost; 2000 May; 83(5):652-6. PubMed ID: 10823256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.